ProMetic and Serono Sign a Development and Collaboration Agreement
Development revenues for ProMetic of up to £550,000 (approx. $C1.3M)
Serono will fund the development of an affinity adsorbent to isolate and purify a protein of interest to Serono. A Mimetic Ligand(TM) will be selected from ProMetic´s Intelligent Combinatorial Libraries and will be designed to enhance Serono´s already rigorous therapeutic purification procedures.
"We are thrilled that Serono, a world leader in recombinant products, has chosen ProMetic´s technology to further enhance its manufacturing and purification processes!, commented Pierre Laurin, President and CEO of ProMetic Life Sciences Inc. !This agreement confirms once again the establishment of ProMetic as a world leader in the plasma and recombinant protein purification market!.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.